Display options
Cite
Liu J, Sun XF, Qian J, et al. Immunochemotherapy for primary central nervous system lymphoma with rituximab, methotrexate, cytarabine and dexamethasone: Retrospective analysis of 18 cases. Mol Clin Oncol. 2015;3(4):949-953doi: 10.3892/mco.2015.566.
Liu, J., Sun, X. F., Qian, J., Bai, X. Y., Zhu, H., Cui, Q. U., Li, X. Y., Chen, Y. D., Wang, Y. M., & Liu, Y. B. (2015). Immunochemotherapy for primary central nervous system lymphoma with rituximab, methotrexate, cytarabine and dexamethasone: Retrospective analysis of 18 cases. Molecular and clinical oncology, 3(4), 949-953. https://doi.org/10.3892/mco.2015.566
Liu, Jing, et al. "Immunochemotherapy for primary central nervous system lymphoma with rituximab, methotrexate, cytarabine and dexamethasone: Retrospective analysis of 18 cases." Molecular and clinical oncology vol. 3,4 (2015): 949-953. doi: https://doi.org/10.3892/mco.2015.566
Liu J, Sun XF, Qian J, Bai XY, Zhu H, Cui QU, Li XY, Chen YD, Wang YM, Liu YB. Immunochemotherapy for primary central nervous system lymphoma with rituximab, methotrexate, cytarabine and dexamethasone: Retrospective analysis of 18 cases. Mol Clin Oncol. 2015 Jul;3(4):949-953. doi: 10.3892/mco.2015.566. Epub 2015 May 12. PMID: 26171213; PMCID: PMC4486824.
Copy Download .nbib Format: NLM
Share it on

Mol Clin Oncol. 2015 Jul;3(4):949-953. doi: 10.3892/mco.2015.566. Epub 2015 May 12.

Immunochemotherapy for primary central nervous system lymphoma with rituximab, methotrexate, cytarabine and dexamethasone: Retrospective analysis of 18 cases.

Molecular and clinical oncology

Jing Liu, Xue-Fei Sun, Jun Qian, Xue-Yan Bai, Hong Zhu, Q U Cui, Xiao-Yan Li, Yue-Dan Chen, Ya-Ming Wang, Yuan-Bo Liu

Affiliations

  1. Department of Hematology, Beijing Tiantan Hospital, Capital Medical University, Beijing 100050, P.R. China.
  2. Department of Neurosurgery, Navy General Hospital of People's Liberation Army, Beijing 100048, P.R. China.

PMID: 26171213 PMCID: PMC4486824 DOI: 10.3892/mco.2015.566

Abstract

The incidence of primary central nervous system lymphoma (PCNSL) has increased in the last two decades and the clinical research regarding the treatment for PCNSL patients has also increased. However, the optimal induction chemotherapy has not been fully established. In the present retrospective study, the aim was to analyze the outcome in PCNSL patients treated with the combination of rituximab, methotrexate (MTX), cytarabine (Ara-C) and dexamethasone (R-MAD). Eighteen patients from Beijing Tiantan Hospital (Beijing, China) between January 2010 and March 2014 were newly diagnosed with PCNSL [diffuse large B-cell lymphoma (DLBCL) type] and received R-MAD as first-line treatment. The dosage was as follows: 375 mg/m

Keywords: immunochemotherapy; primary central nervous system lymphoma; retrospective analysis; rituximab; serum lactate dehydrogenase

References

  1. Hematol Oncol. 2013 Jun;31(2):57-64 - PubMed
  2. Cancer. 1997 Jun 15;79(12):2409-13 - PubMed
  3. Neurology. 2014 Jul 15;83(3):235-9 - PubMed
  4. Ann Oncol. 1997 Mar;8(3):227-34 - PubMed
  5. J Clin Oncol. 2003 Dec 15;21(24):4489-95 - PubMed
  6. Lancet. 2009 Oct 31;374(9700):1512-20 - PubMed
  7. Ann Oncol. 2004 Jan;15(1):129-33 - PubMed
  8. Oncol Rep. 2009 Sep;22(3):439-49 - PubMed
  9. Curr Opin Neurol. 2009 Dec;22(6):675-80 - PubMed
  10. Curr Treat Options Oncol. 2013 Dec;14(4):539-52 - PubMed
  11. J Clin Oncol. 2006 Mar 10;24(8):1281-8 - PubMed
  12. J Neurooncol. 2010 Jul;98(3):385-93 - PubMed
  13. Neurology. 2011 Mar 8;76(10):929-30 - PubMed
  14. Neurology. 2006 May 9;66(9):1435-8 - PubMed
  15. J Clin Oncol. 2003 Dec 15;21(24):4483-8 - PubMed
  16. Lancet Neurol. 2009 Jun;8(6):581-92 - PubMed
  17. Leuk Lymphoma. 2014 Nov;55(11):2497-501 - PubMed
  18. J Clin Oncol. 2005 Aug 1;23(22):5034-43 - PubMed

Publication Types